The world of medicine is being split into two distinct classes. On one side, the Global South is seeing a revolution in access as patents for weight-loss drugs like semaglutide expire, allowing Indian firms to offer generics for as little as $15 a month. On the other side, Novo Nordisk has secured FDA approval for 'Wegovy HD,' a premium, higher-dose variant designed to protect its market share among the wealthy in the West. This creates a troubling 'metabolic divide' where the wealthy receive high-potency treatments while the middle class and the poor are left with legacy options or generics of varying quality. While we celebrate the collapse of prices that helps the suffering, we must be wary of a system that commodifies basic health into 'premium' and 'standard' tiers. The health of a nation should not be a luxury good. This move toward VIP pharmaceutical dosing is part of a larger trend of 'premium citizenship' where the best of everything—from water to medicine—is fenced off for those with the deepest pockets. We must ask what kind of society we are building when the very shape of our bodies is determined by our bank accounts. True health comes from a balanced life and a community that supports virtuous choices, but when medicine is required, it should be administered with an eye toward the common good, not just the quarterly earnings of a pharmaceutical giant. We must guard against the enclosure of the medical commons and ensure that the gift of healing remains accessible to all who need it.